[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regencell Bioscience Holdings Ltd (RGC)

Regencell Bioscience Holdings Ltd (RGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,351,204
  • Shares Outstanding, K 494,489
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,580 K
  • EBIT $ 0 M
  • EBITDA $ -4 M
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 116.39% (-6.30%)
  • Historical Volatility 76.81%
  • IV Percentile 6%
  • IV Rank 7.64%
  • IV High 310.58% on 07/03/25
  • IV Low 100.32% on 10/20/25
  • Expected Move (DTE 27) 5.36 (20.21%)
  • Put/Call Vol Ratio 1.97
  • Today's Volume 104
  • Volume Avg (30-Day) 532
  • Put/Call OI Ratio 1.20
  • Today's Open Interest 5,135
  • Open Int (30-Day) 5,658
  • Expected Range 21.15 to 31.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/17
See More
  • Average Estimate $0.34
  • Number of Estimates 6
  • High Estimate $0.39
  • Low Estimate $0.30
  • Prior Year $0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.50 +1.96%
on 05/12/26
32.00 -18.75%
on 05/07/26
-3.29 (-11.23%)
since 04/22/26
3-Month
20.00 +30.00%
on 03/09/26
40.00 -35.00%
on 04/01/26
-3.17 (-10.87%)
since 02/20/26
52-Week
9.39 +176.89%
on 07/02/25
83.60 -68.90%
on 06/16/25
+14.38 (+123.78%)
since 05/22/25

Most Recent Stories

More News
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC)...

RGC : 25.70 (-4.81%)
Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

Alert: Regencell's $14 Billion Market Valuation Built on Zero Revenue Collapsed 18.56% After DOJ Subpoena Revealed Alleged Market Manipulation Investigation

RGC : 25.70 (-4.81%)
RGC Deadline Alert: Levi & Korsinsky Reminds Regencell Bioscience Holdings (RGC) Investors of Securities Class Action Deadline on June 23, 2026

Important Notice Regarding Alleged Market Manipulation Vulnerability and Concealed DOJ Investigation Risk at Regencell Bioscience

RGC : 25.70 (-4.81%)
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

NEW YORK , May 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC).

RGC : 25.70 (-4.81%)
RGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

NEW YORK , May 18, 2026 /PRNewswire/ --

RGC : 25.70 (-4.81%)
Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , May 18, 2026 /PRNewswire/ --  Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit...

RGC : 25.70 (-4.81%)
Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , May 15, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

RGC : 25.70 (-4.81%)
RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their Options

RGC : 25.70 (-4.81%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC)...

RGC : 25.70 (-4.81%)
RGC DEADLINE: Levi & Korsinsky Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA — RGC Investors Who Lost Money During the Class Period Have Until June 23, 2026 to Seek Appointment

RGC : 25.70 (-4.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Regencell Bioscience Holdings Limited is an early-stage bioscience company which focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum...

See More

Key Turning Points

3rd Resistance Point 29.29
2nd Resistance Point 28.83
1st Resistance Point 27.91
Last Price 25.70
1st Support Level 26.54
2nd Support Level 26.09
3rd Support Level 25.17

See More

52-Week High 83.60
Fibonacci 61.8% 55.25
Fibonacci 50% 46.49
Fibonacci 38.2% 37.74
Last Price 25.70
52-Week Low 9.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.